Drugs / DAVAMOTECAN PEGADEXAMER
Trials 12 · a red edge is where a trial was stopped
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAVAMOTECAN PEGADEXAMER | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802201 ↗ |
| Known as | Cerulean | “CRLX101 (Cerulean)” NCT01625936 ↗ |
| Known as | Crlx-101 drug substance | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802201 ↗ |
| Known as | CRLX101 | “Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors” NCT00333502 ↗ |
| Known as | EP0057 | “EP0057 (formerly CRLX101) is an investigational nanoparticle-drug” PMID 33390325 ↗ Dec 2020 |
| Known as | IT-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00753740 ↗ |
| Known as | NLG207 | “NLG207 (formerly CRLX101) is a nanoparticle-drug conjugate (NDC) of the potent topoisomerase I inhibitor, camptothecin (CPT).” PMID 32897402 ↗ Sep 2020 |
| Action | Inhibit | “cytotoxic topoisomerase-1 inhibitor camptothecin” NCT01612546 ↗ |
| Modality | Other / unclassified | “CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.” NCT00333502 ↗ |
| Route | Intravenous | “when administered intravenously” NCT00333502 ↗ |
| Target | HIF1A | “CRLX101-mediated inhibition of HIF-1α” NCT01652079 ↗ |